Synagis injection: reconstitution no longer required

Synagis (palivizumab), AbbVie's respiratory syncytial virus (RSV) prophylactic for use in high-risk infants and children under two years, has been reformulated and is now available as a solution for injection.

Further information
View Synagis drug record
Summary of Product Characteristics
Manufacturer: AbbVie

The licensed indications, dosing, contraindications and warnings for use, and safety profile for the solution are identical to that of the lyophilised powder formulation which has now been discontinued.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more